Skip to content

GeneDx Holdings WGS Accrued severance

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$1.89B-24.3%
Enterprise value$1.89B-22.8%
P/S4.3×-3.3×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept wgs:AccruedSeveranceCurrent.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's accrued severance.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GeneDx Holdings's accrued severance?
GeneDx Holdings (WGS) reported accrued severance of $742K in Q1 2026.
How has GeneDx Holdings's accrued severance changed year-over-year?
GeneDx Holdings's accrued severance decreased by 32.3% year-over-year, from $1.1M to $742K.
What is the long-term trend for GeneDx Holdings's accrued severance?
Over 3 years (2022 to 2025), GeneDx Holdings's accrued severance has grown at a -45.5% compound annual growth rate (CAGR), from $4.77M to $771K.